跳到正文
原文
NEJM· C. Michael Gibson P. Gabriel Steg M. Cecilia Bahit Rasha Al-Lamee Shamir R. Mehta Roxana Mehran Jeffrey I. Weitz Shinya Goto Jose Carlos Nicolau Renato D. Lopes Junbo Ge Nebojsa Tasic Dominick J. Angiolillo Suzanne J. Baron Ajay J. Kirtane Denis Xavier Satoshi Yasuda Basil S. Lewis Duk-Woo Park Jan H. Cornel Thomas W. Johnson Jaroslaw Trebacz Daniel Duerschmied Christoph Bode Bela Merkely Maria Dorobantu Dragos Vinereanu Zuzana Motovska Hector Bueno Jose Luis Lopez-Sendon Gregory Ducrocq Giuseppe Ambrosio Lesley Burgess Allan Bohm Chern-En Chiang Joao Morais Alan Fong Umit Guray Jose Luis Leiva-Pons Pascal Vranckx Harvey D. White Sasko Kedev Marco Valgimigli Duško Cerovec Dimitris Tousoulis Gemma Figtree Thuong Dung Ho Rody G. Sy Morten Bøttcher Kurt Huber Rimvydas Slapikas Andrejs Erglis Jack Wei Chieh Tan Christian Pincetti Karen S. Pieper Kenneth W. Mahaffey Carolyn S.P. Lam S. Claiborne Johnston Graeme J. Hankey Jennifer S. Li Luke Zheng Ronald Aronson Danshi Li Ravi Notani Philippe Vieira Pires Thomas J. Povsic Alistair C. Lindsay Alexei Plotnikov Hsiaowei Deng Elliot S. Barnathan and Robert A. Harringtonthe LIBREXIA ACS Committees and Investigators*·· 2026-08-29精选AI 评分62

NEJM 发表 milvexian 联合抗血小板治疗用于急性冠脉综合征后的研究

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

AI 导读

NEJM 刊出研究《Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event》,发表于第 395 卷第 16 期第 1575-1584 页,日期为 2026 年 10 月 22 日。

推荐理由

NEJM 刊出 milvexian 用于急性冠脉综合征后联合抗血小板治疗的试验结果,可供关注口服抗凝药在 ACS 二级预防中定位的读者参考。

来源:NEJM · nejm.org